SPOTLIGHT -
Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis
Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
Read More
The Future of Multiple Myeloma
Targeted Treatment Options in Multiple Myeloma
Trials in Relapsed/Refractory Multiple Myeloma
Treatment Options in Relapsed/Refractory Multiple Myeloma
Options for Transplant Ineligible Patients in Multiple Myeloma
Maintenance Therapy in Multiple Myeloma
The Role of Transplant in Multiple Myeloma
Looking at GRIFFIN Trial Data
A Look at the ENDURANCE Trial
Newly Diagnosed Multiple Myeloma
Introduction to Multiple Myeloma
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
